References
- www.byetta.com, Amylin Pharmaceuticals, Inc. Exenatide prescribing information
- Calara F, Taylor K, Han J, Zabala E, Moo Car E, Wintle M. A randomized, open label, cross over study examining the effect of injection site bioavailability of exenatide (Synthetic Enedin-4). Clinical Therapeutics 2005; 27(2)210–215
- Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5)1083–91
- Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53(9)2397–403
- Micromedex®. Healthcare Series [intranet database]. Thomson Micromedex, Greenwood Village, CO. Version 5.1
- Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exanatide-113 clinical study group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11)2628–35
- DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5)1092–1100
- http://www.byetta.com/patient/byetta_pen_122.jsp?reqNavId=2.3, Amylin Pharmaceuticals, Inc
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2)239–45